One of my mentors used to say it plainly: when we treat adults for addiction, we are often treating stage four cancer. The damage is extensive. The window for full recovery is narrower. By the time most people reach formal treatment, addiction has already reshaped their relationships, their neurological architecture, their sense of identity, and in many cases, their physical health. We intervene late and then wonder why outcomes are so difficult.
But there is a point where we can intervene early. That place is adolescence, and we are largely failing to show up there.
The Adolescent Treatment Gap is a Crisis We're Choosing to Ignore
Teen substance use disorders are not rare. According to SAMHSA's 2024 National Survey on Drug Use and Health, approximately 7.8% of adolescents aged 12 to 17, roughly 2 million young people, had a substance use disorder in the past year. The fentanyl crisis has made the stakes dramatically higher, with overdose now the leading cause of death among Americans aged 18 to 45.
Yet specialized adolescent addiction treatment programs remain scarce, and most existing programs are built around adult models that do not account for the developmental, psychological, and social realities of being a teenager. Adolescents placed in programs designed around adult models, treated with protocols built for a different population, tend to disengage, and disengagement at this stage can mean years of lost opportunity.
Many are also residential programs that pull young people out of school and from their families at exactly the moment when connection and stability matter most. The adolescent who needs help is rarely the one who can disappear into a program for months. They are students with families that must stay involved and a future still being built.
Why Adolescence Is the Highest-Leverage Point
From a psychiatric standpoint, early intervention with adolescents is categorically different from what we do with adults. The adolescent brain is still developing, particularly the prefrontal cortex, which governs impulse control and risk assessment. This developmental window cuts both ways: it makes teenagers more vulnerable to substances, but it also means they retain a neurological flexibility that diminishes with age. There is still room to redirect. The patterns are real, but they have not yet become the architecture of a life. There is still room to redirect.
What the Field Needs to Build
If we are serious about bending the curve on addiction, adolescent-specific treatment must become a priority. That means building programs that enable teenagers to stay in school while receiving intensive clinical support. Intensive outpatient models designed specifically for adolescents, scheduled around the school day, are not a compromise. They are often clinically superior to residential alternatives because they allow young people to practice new skills in the real environments where they need them.
It means integrating families into treatment from the beginning. The research tells us outcomes improve when the relational system surrounding a young person is actively engaged.
It means addressing psychiatric comorbidities alongside addiction. Anxiety, depression, trauma, and ADHD are not separate problems to sequence after treatment. They are intertwined with it. And it means confronting the underutilization of medication-assisted treatment: among adolescents with opioid use disorder, only one in four receives buprenorphine or naltrexone, despite a clear evidence base. We would not accept that rate of non-treatment for any other serious medical condition in young people.
The Investment That Pays Off for a Lifetime
My mentor's analogy has stayed with me because it captures something true and uncomfortable about how we have organized addiction care. If we want to change the trajectory of this epidemic, we cannot only treat it after it has fully taken hold. We need to get there earlier, when the brain is still developing, when the patterns are still forming, when a young person's future is still genuinely open.
Intervening with a teenager is no guarantee. Nothing in this field is. But it is the closest thing we have to catching this illness early. And in medicine, early intervention has always been where the greatest gains are made. We know where the leverage is. The question is whether we are willing to build the programs and develop the clinical expertise to make a true difference.
Joseph Nissenfeld, M.D., is the medical director of Elevate Point, a behavioral health treatment center based in Brooklyn.
